Wockhardt’s ZAYNICH Wins FDA Approval for Drug-Resistant cUTIs
MUMBAI, India & SHORT HILLS, N.J., May 30, 2026 Wockhardt has achieved a historic milestone with the U.S. Food...
daraxonrasib
Advertisement
Bristol Myers Squibb Camzyos Gains FDA Priority Review
PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...
Revolution Medicines Daraxonrasib Doubles Survival in PDAC
REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...
Revolution Medicines Publishes Daraxonrasib Pancreatic Cancer Data in NEJM
Redwood City, Calif., May 6, 2026 Revolution Medicines, Inc. announced the publication of important Phase 1/2 clinical trial data...
Revolution Medicines Advances Daraxonrasib Into Phase 3
REDWOOD CITY, Calif., April 2, 2026 Revolution Medicines has announced the initiation of patient dosing in its global Phase...
Advertisement
